Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 [Yahoo! Finance]
Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Kymera Therapeutics to Participate in Upcoming February Investor Conferences [Yahoo! Finance]
Kymera Therapeutics to Participate in Upcoming February Investor Conferences
Kymera Therapeutics (NASDAQ:KYMR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $138.00 price target on the stock.